Indication
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Medicine details
- Medicine name:
- elranatamab (Elrexfio)
- SMC ID:
- SMC2669
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 09 September 2024
- SMC meeting date:
- 06 August 2024
- Patient group submission deadline:
- 03 June 2024